|Category||Haematology >> Specialised Coagulation Services|
Rivaroxaban is a direct oral anticoagulant (DOAC) which exerts its anticoagulant effect through its ability to directly inhibit Coagulation Factor Xa. Plasma Rivaroxaban levels are measured in mass concentration by chromogenic anti-Xa assay using drug-specific calibrators.
Recommended as an option for (NICE Guidelines 2016 - KTT16):
DOAC monitoring is not generally required; however measurement may be useful where clearance is compromised or where patients are actively bleeding.
BCSH Guidelines (2014) Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis:
Dose Peak (mean and range) Trough (mean and range); Rivaroxaban 10 mg od 125 ng/mL (91 -195) 9 ng/mL (1 – 38); Rivaroxaban 20 mg od 223 ng/mL (160 – 360) 22 ng/mL (4 – 96);
Peak – 3 hours post-dose
|Sample & container required||4.5 mL sodium citrate (pale blue top) adults; 1.8 mL sodium citrate (pale blue top) paediatrics|
|Turnaround time||<24 hours (core hours)|
Please Note: Samples will be rejected if under/over-filled, clotted or haemolysed